GSK Phase III Exon Skipping Trial Has Completed Recruitment – August 10th, 2012

Study DMD114044: A phase III, randomized, double blind, placebo-controlled clinical study to assess the efficacy and safety of GSK2402968 in subjects with Duchenne muscular dystrophy

The study is expected to complete in July 2013, with study results expected in late 2013.  The results will be presented at the first appropriate medical conference.  Note that GSK2402968 will be referred to by its generic name ‘drisapersen’ in future communications.

Sincerely,

John E. Kraus, MD, PhD                                Padraig Wright, MD, PhD

john.e.kraus@gsk.com                                 padraig.x.wright@gsk.com

0 Comments
Posted in Uncategorized

Leave a Reply

Leave a Reply

or chancel